[Inhibitory effect on rabbit peritoneal leukocyte and macrophage chemotaxis by sera from patients with pulmonary sarcoidosis: significance of serum chemotactic inhibitor in sarcoidosis].
Untreated 45 patients with pulmonary sarcoidosis were studied with respect to the presence of serum chemotactic inhibitor. Chemotactic assay was performed by modified Boyden chambers using polymorphonuclear leukocytes (PMNs) obtained from rabbit peritoneal exudate as indicator cells. Chemotaxis of PMNs was significantly suppressed by sera from patients with hilar lymphadenopathy and/or pulmonary infiltration compared with those from healthy subjects (P less than 0.001), whereas there was no significant difference between healthy subjects and patients who revealed complete remission on the chest X-ray films. This would be due to the serum chemotactic inhibitor rather than to the chemotactic deactivation of the cells. This inhibitor exhibited a direct inhibitory effect on the cells. In addition, the inhibitory effect remained even after serum was removed from the cells by washing. The inhibitor was heat-stable at 56 degrees C for 30 minutes in character. These features closely agreed with those of cell-directed inhibitor as described by Ward et al. Furthermore, untreated 30 patients with pulmonary sarcoidosis were examined by modified Boyden chambers using rabbit peritoneal macrophages as indicator cells. Macrophage chemotaxis was significantly suppressed by sera from patients who had tuberculin anergy compared with those from healthy subjects and patients who exhibited positive tuberculin reaction (P less than 0.001). In addition, there was close relationship between the degree of chemotactic suppression and the duration of disease (P less than 0.001), angiotensin-converting-enzyme activity (P less than 0.01). It was discussed that the cell-directed inhibitor might play a role in pathogenesis of sarcoidosis.